BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET

Company Participants

John Bluth - Investor Relations

Jon Stonehouse - Chief Executive Officer

Charlie Gayer - Chief Commercial Officer

Jinky Rosselli - Chief Data & Insights Officer

Anthony Doyle - Chief Financial Officer

Conference Call Participants

Tazeen Ahmad - Bank of America

Stacy Ku - Cowen & Co.

Liisa Bayko - Evercore ISI

Serge Belanger - Needham & Company

Operator

Good morning and welcome to the BioCryst Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference to Mr. John Bluth at BioCryst. Please go ahead.

John Bluth

Thank you, Maria. Good morning and welcome to BioCryst's third quarter 2023 corporate update and financial results conference call. Today’s press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief Data & Insights Officer, Jinky Rosselli. Following our remarks, we will answer your questions.

As a reminder, tomorrow at 1:00 p.m. Eastern Time will be hosting an R&D Day where we plan to describe our drug discovery process and introduce additional therapies from our pipeline. So today we'll focus on ORLADEYO and tomorrow we'll take a deep dive and answer your question on our pipeline programs.

Before we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company’s future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company’s documents filed with the Securities and Exchange Commission which can be accessed on our website. In addition, today's conference call includes non-GAAP, pro-forma financial measures. For a reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the press release section of our Investor Relations website at biochrist.com.

Now, I’d like to turn the call over to Jon Stonehouse.

Jon Stonehouse

Thanks, John. Third quarter ORLADEYO revenue of $85.7 million was another strong quarter of performance and gives us a high degree of confidence we will achieve our goal of no less than $320 million for the year and remain on-track for the $1 billion at peak. This growing revenue along with the discipline around our capital allocation put us in a very strong financial position heading into the end of the year. Since we have more time today to discuss ORLADEYO, we’ll go deeper into what we see in the market and how we see the market changing overtime.